Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Dermatol ; 61(1): 71-83, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34173672

ABSTRACT

OBJECTIVES: We present the results of 11 patients with hypochromic lesions treated with antifibrotic agents delivered through the MMP® technique. METHODS: Eleven patients with hypochromic lesions because of external injuries were treated at a single clinic with 5-fluorouracil (5-FU) and/or bleomycin using the MMP® drug delivery technique. Treatment sessions were repeated at 30-day intervals until patient satisfaction. The primary outcome was repigmentation of the lesions, assessed independently by two dermatologists and by the patient. RESULTS: The MMP® technique injected 0.048 mg/cm2 of 5-FU or 0.0028 U/cm2 of bleomycin. The accumulated 5-FU and bleomycin density per patient ranged from 0.02 to 0.77 mg and 0.0022 to 0.2800 U/ml, respectively. Patients were treated with 1 to 6 MMP® sessions with 5-FU (3 patients), bleomycin (6 patients), or both drugs (2 patients). After the last session, all patients had a significant improvement (>75%) of the lesions compared to baseline. There were no procedure-related short- or long-term adverse effects in any of the participants up to their last follow-up visit. CONCLUSIONS: The injection of antifibrotic agents using the MMP® technique was effective and safe in the treatment of hypochromic lesions. This can be a new therapeutic option for these lesions.


Subject(s)
Bleomycin , Drug Delivery Systems , Fluorouracil , Pigmentation Disorders , Antifibrotic Agents/administration & dosage , Bleomycin/administration & dosage , Fluorouracil/administration & dosage , Humans , Iatrogenic Disease , Pigmentation Disorders/drug therapy , Treatment Outcome
2.
Int J Dermatol ; 58(6): 750-755, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30828798

ABSTRACT

BACKGROUND: Even though dermatologists often perform drug delivery procedures, it is necessary to assess their safety. OBJECTIVE: Quantify the amount of medication delivered using the MMP drug delivery technique and outline other safety parameters. METHODS: Using a simple and novel technique, we attempted to quantify the amount of medication delivered by weighing human skin samples before and after delivery. RESULTS: In drug delivery done on human skin using a liquid with a density of 1,271,460 µg/ml (the values expressed in this manuscript are in µg), a needling density of 570 perforations/cm2 , and a needling depth of 300 microns, we estimate that 1,175 µg/cm2 were delivered (standard deviation 601 µg/cm2 , standard error 190 µg/cm2 ). LIMITATIONS: This result is only applicable to the protocol proposed in this study for the MMP drug delivery technique. CONCLUSION: The MMP drug delivery technique injects small amounts of medication (1,175 µg/cm2 ) homogeneously into the dermis.


Subject(s)
Dermatologic Agents/administration & dosage , Drug Delivery Systems/instrumentation , Tattooing/instrumentation , Drug Delivery Systems/methods , Humans , Injections, Subcutaneous/instrumentation , Injections, Subcutaneous/methods , Skin , Skin Absorption , Tattooing/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...